Author Affiliations: Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Agency for Healthcare Research and Quality, Rockville, Md; and Center for Education and Research on Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, Pa.
Loss of bone mass accompanies the aging process and increases risk of
fracture, particularly in women. The principal sites of osteoporotic fractures
are the forearm, vertebral body, and hip.1
Pharmacological theory2 and in vivo3 and animal4 model observations
have suggested that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
(statins) may increase bone mineral density, raising the hope that these drugs
also may be useful in reducing risk of osteoporotic fractures.
Hennessy S, Strom BL. Statins and Fracture Risk. JAMA. 2001;285(14):1888-1889. doi:10.1001/jama.285.14.1888